Suppr超能文献

甲状腺癌的转移休眠和进展:靶向转移前沿的细胞。

Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.

机构信息

Divisions of Endocrinology and Oncology, The Ohio State University College of Medicine and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA.

出版信息

Thyroid. 2011 May;21(5):487-92. doi: 10.1089/thy.2011.2121. Epub 2011 Apr 10.

Abstract

BACKGROUND

Metastatic dormancy, or the ability of cancer cells to survive but not progress in metastatic environments, is now recognized to be a common occurrence in cancer.

SUMMARY

From a clinical perspective, this phenomenon is common in metastatic well-differentiated thyroid cancer, whereby patients often present with distant metastases that remain stable for years after removal of the primary tumor and subsequent treatment. Experimental data suggest that metastases can develop throughout the life of a cancer and that progression in the distant environment depends on the biology of the cancer cells that metastasize as well as that of the various microenvironments they encounter. A firm understanding of how thyroid cancer cell progression is regulated in different metastatic environments is necessary to devise effective therapies targeting progressive metastatic thyroid cancer.

CONCLUSION

In this review, current models of metastatic progression and factors that regulate late-stage metastatic progression that are particularly relevant for thyroid cancer are discussed.

摘要

背景

转移休眠,即癌细胞在转移环境中能够存活但不会进展的能力,现在被认为是癌症的常见现象。

概述

从临床角度来看,这种现象在分化良好的甲状腺癌转移中很常见,患者通常表现为远处转移,在原发肿瘤和后续治疗切除后,这些转移灶多年来仍保持稳定。实验数据表明,转移可以在癌症的整个生命周期中发生,并且在远处环境中的进展取决于转移的癌细胞的生物学特性以及它们所遇到的各种微环境。深入了解甲状腺癌细胞在不同转移环境中的进展是如何受到调控的,对于设计针对进展性转移性甲状腺癌的有效治疗方法至关重要。

结论

在这篇综述中,讨论了当前的转移进展模型以及调控晚期转移进展的因素,这些因素对甲状腺癌尤其相关。

相似文献

1
Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.
Thyroid. 2011 May;21(5):487-92. doi: 10.1089/thy.2011.2121. Epub 2011 Apr 10.
2
Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications.
Endocrine. 2020 Oct;70(1):24-35. doi: 10.1007/s12020-020-02453-8. Epub 2020 Aug 11.
3
Distant metastases in differentiated thyroid carcinomas: a clinical and pathologic study.
Hum Pathol. 1990 Mar;21(3):283-90. doi: 10.1016/0046-8177(90)90228-w.
4
LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER AND DISTANT METASTASES.
Endocr Pract. 2017 Oct;23(10):1193-1200. doi: 10.4158/EP171924.OR. Epub 2017 Jul 13.
5
Standard and emerging therapies for metastatic differentiated thyroid cancer.
Oncologist. 2010;15(2):146-56. doi: 10.1634/theoncologist.2009-0190. Epub 2010 Feb 8.
6
Surveillance for Differentiated Thyroid Cancer Recurrence.
Endocrinol Metab Clin North Am. 2019 Mar;48(1):239-252. doi: 10.1016/j.ecl.2018.11.008.
7
Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea.
PLoS One. 2020 Aug 25;15(8):e0238207. doi: 10.1371/journal.pone.0238207. eCollection 2020.
8
[Lymph node and distant metastases of thyroid gland cancer. Metastases in the thyroid glands].
Pathologe. 2015 Nov;36 Suppl 2:171-5. doi: 10.1007/s00292-015-0071-6.
10
Mechanisms of Metastatic Tumor Dormancy and Implications for Cancer Therapy.
Int J Mol Sci. 2019 Dec 6;20(24):6158. doi: 10.3390/ijms20246158.

引用本文的文献

1
Metastatic differentiated thyroid cancer: worst prognosis in patients with metachronous metastases.
Endocrine. 2023 Jul;81(1):90-97. doi: 10.1007/s12020-023-03302-0. Epub 2023 May 12.
4
Recurrence of Papillary Thyroid Cancer: A Systematic Appraisal of Risk Factors.
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1392-1406. doi: 10.1210/clinem/dgab836.
5
Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications.
Endocrine. 2020 Oct;70(1):24-35. doi: 10.1007/s12020-020-02453-8. Epub 2020 Aug 11.
8
Clonal Reconstruction of Thyroid Cancer: An Essential Strategy for Preventing Resistance to Ultra-Precision Therapy.
Front Endocrinol (Lausanne). 2019 Jul 18;10:468. doi: 10.3389/fendo.2019.00468. eCollection 2019.
9
Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Curr Oncol Rep. 2018 Sep 11;20(10):82. doi: 10.1007/s11912-018-0736-4.
10
RCAN1-4 is a thyroid cancer growth and metastasis suppressor.
JCI Insight. 2017 Mar 9;2(5):e90651. doi: 10.1172/jci.insight.90651.

本文引用的文献

1
The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts.
Semin Cancer Biol. 2011 Apr;21(2):139-46. doi: 10.1016/j.semcancer.2011.01.002. Epub 2011 Jan 18.
2
Vaccines and immunotherapeutics for the treatment of malignant disease.
Clin Dev Immunol. 2010;2010:697158. doi: 10.1155/2010/697158. Epub 2010 Sep 26.
3
Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.
Endocr Relat Cancer. 2010 Oct 29;17(4):989-99. doi: 10.1677/ERC-10-0168. Print 2010 Dec.
4
Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells.
Laryngoscope. 2010 Jul;120(7):1383-90. doi: 10.1002/lary.20915.
5
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.
Oncogene. 2010 Aug 26;29(34):4741-51. doi: 10.1038/onc.2010.215. Epub 2010 Jun 7.
6
The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies.
Clin Endocrinol (Oxf). 2010 May;72(5):702-8. doi: 10.1111/j.1365-2265.2009.03699.x.
7
Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth.
Eur J Cancer. 2010 May;46(7):1181-8. doi: 10.1016/j.ejca.2010.02.027. Epub 2010 Mar 19.
8
Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer.
J Clin Endocrinol Metab. 2010 May;95(5):2325-33. doi: 10.1210/jc.2009-2564. Epub 2010 Mar 5.
9
Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation.
Cancer Res. 2010 Feb 15;70(4):1668-78. doi: 10.1158/0008-5472.CAN-09-2470. Epub 2010 Feb 2.
10
Rab27a and Rab27b control different steps of the exosome secretion pathway.
Nat Cell Biol. 2010 Jan;12(1):19-30; sup pp 1-13. doi: 10.1038/ncb2000. Epub 2009 Dec 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验